緊急避妊薬市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、流通チャネル別、地域別、競合別、2020～2030年

緊急避妊薬の世界市場規模は2024年に6億442万米ドルとなり、2030年までのCAGRは4.31%で予測期間には7億7,970万米ドルに達すると予測されています。

緊急避妊薬（ECP）は、しばしばモーニングアフターピルまたはデイアフターピルと呼ばれ、無防備な性交渉や避妊失敗後の妊娠を防ぐために使用される避妊の一形態です。これらのピルは、避妊していない性交渉の後、できるだけ早く服用するように設計されており、定期的または継続的な避妊を目的としたものではありません。ECPの主な目的は、通常の避妊法に失敗した場合、避妊法を使用しなかった場合、または使用法を誤った場合に、妊娠のリスクを軽減することです。ECPは、成立した妊娠を終了させるためのものではなく、中絶の一形態でもありません。ECPは、無防備な性交渉の後、できるだけ早く服用するのが最も効果的です。そのため、速やかに服用することが重要です。ECPの中には、無防備な性交渉後72時間（3日間）まで有効なものもあれば、120時間（5日間）まで有効なものもあります。ECPは一般的にほとんどの人にとって安全であり、長期的な健康リスクはないと考えられています。しかし、他の薬と同様に、吐き気、嘔吐、乳房の圧痛、疲労、月経パターンの変化などの副作用の可能性があります。

主な市場促進要因

無防備な性交渉の高発生率

主な市場課題

偏見と誤った情報

主な市場動向

遠隔医療とeコマース

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の緊急避妊薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（混合ピル、プロゲステロンピル、その他）
  • 流通チャネル別（小売店、オンラインストア、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 アジア太平洋地域の緊急避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の緊急避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の緊急避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の緊急避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの緊急避妊薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の緊急避妊薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Afaxys Pharma LLC
• Bayer AG
• Combe Inc.
• Foundation Consumer Healthcare LLC
• Gedeon Richter Plc
• HLL Lifecare Ltd.
• Knoll Healthcare Pvt. Ltd.
• Laboratoire HRA Pharma SAS
• Lupin Ltd.
• Mankind Pharma Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Emergency Contraceptive Pills Market was valued at USD 604.42 Million in 2024 and is expected to reach USD 779.70 Million in the forecast period with a CAGR of 4.31% through 2030. Emergency Contraceptive Pills (ECPs), often referred to as "morning-after pills" or day-after pills, are a form of contraception used to prevent pregnancy after unprotected sexual intercourse or contraceptive failure. These pills are designed to be taken as soon as possible after unprotected sex and are not intended for regular or ongoing contraception. The primary purpose of ECPs is to reduce the risk of pregnancy when regular contraception methods fail, are not used, or were used incorrectly. They are not intended to terminate an established pregnancy, and they are not a form of abortion. ECPs are most effective when taken as soon as possible after unprotected sex. Their effectiveness decreases with time, so it's important to take them promptly. Some ECPs are effective up to 72 hours (3 days) after unprotected sex, while others may have a longer window of effectiveness, such as up to 120 hours (5 days). ECPs are generally considered safe for most people and are not associated with long-term health risks. However, like all medications, they may have potential side effects, which can include nausea, vomiting, breast tenderness, fatigue, and changes in menstrual patterns.

Key Market Drivers

High Incidence of Unprotected Sex

Emergency contraceptive pills (ECPs) are specifically designed to prevent unintended pregnancies when regular contraception methods have failed, were not used, or were used incorrectly. Unprotected sex carries a higher risk of pregnancy, and ECPs provide a timely and effective option to reduce this risk. Unprotected sex can result from a variety of circumstances, including contraceptive method failure (e.g., condom breakage), lack of access to contraception, sexual assault, or unexpected sexual encounters. In these emergency situations, individuals may turn to ECPs to prevent an unintended pregnancy. ECPs offer a level of privacy and discretion, allowing individuals to take control of their reproductive health without the need for a healthcare provider's involvement or the disclosure of personal information.

The effectiveness of ECPs decreases with time after unprotected sex. Therefore, individuals who engage in unprotected sex and want to prevent pregnancy are often motivated to obtain and use ECPs as soon as possible, making timeliness a crucial factor. In some cases, individuals may not have access to regular contraception methods, such as birth control pills or condoms. In these situations, ECPs can serve as a backup option to prevent pregnancy. Increasing awareness and education about emergency contraception have led to more people recognizing the availability and benefits of ECPs, which can drive demand. Changing lifestyles, including increased social activities and relationships, may lead to situations where individuals find themselves engaging in unprotected sex unexpectedly. Even when regular contraception methods are used correctly, there is always a small risk of failure. This concern can motivate individuals to use ECPs as an added precaution. In many countries, ECPs are legally available and may be accessible without a prescription. These regulatory factors can contribute to the demand for ECPs in cases of unprotected sex. For individuals who experience anxiety or worry after unprotected sex, the availability of ECPs can provide psychological relief and peace of mind. This factor will help in the development of the Global Emergency Contraceptive Pills Market.

Key Market Challenges

Stigma and Misinformation

Stigma associated with emergency contraception can discourage individuals from seeking or using these pills. This stigma may arise from cultural, religious, or social beliefs that view emergency contraception as morally or socially unacceptable. There is often misinformation and myths surrounding emergency contraceptive pills, which can create confusion and hesitation among potential users. Common myths include misconceptions about their safety, effectiveness, and side effects. Stigma and misinformation can create barriers to accessing emergency contraception. For example, individuals may avoid seeking ECPs from healthcare providers or pharmacies due to fear of judgment or misunderstanding about how the pills work. Misinformation can contribute to a lack of awareness about emergency contraception. Some individuals may not even be aware that ECPs are available or how they can be obtained. The fear of being judged by healthcare providers, pharmacists, or peers can deter individuals from seeking emergency contraception. This fear may be based on the belief that using ECPs implies irresponsible behavior or promiscuity. Cultural and religious beliefs can strongly influence attitudes towards contraception, including emergency contraception. Some cultures and religious groups may consider the use of ECPs as morally unacceptable. Inadequate sexual education can contribute to misinformation about emergency contraception. Comprehensive sex education programs are essential in addressing this challenge and providing accurate information. Misinformation can lead to misconceptions about the side effects of emergency contraception, causing unnecessary concerns or fears about health risks.

Key Market Trends

Telemedicine and E-Commerce

Telemedicine platforms have been providing individuals with the opportunity to consult with healthcare professionals remotely. This includes discussing their need for emergency contraception, receiving guidance on its use, and obtaining prescriptions when necessary. Telemedicine services have made it easier for individuals to access medical advice and prescriptions for emergency contraceptive pills from the comfort and privacy of their homes. Online retailers and e-commerce platforms have been offering emergency contraceptive pills for sale. This allows individuals to purchase these products discreetly and conveniently without visiting a physical pharmacy or healthcare provider. E-commerce platforms have expanded access to emergency contraception, especially for those who may feel uncomfortable or embarrassed discussing the topic in person. Depending on the region and local regulations, some e-commerce platforms may offer both prescription and non-prescription (over the counter) emergency contraceptive pills. This provides consumers with choices based on their specific needs and circumstances. Telemedicine and e-commerce provide a level of privacy and convenience that many individuals find appealing. They can access emergency contraception without face-to-face interactions and without disclosing their personal information to pharmacy staff or healthcare providers. Through telemedicine, individuals can engage in digital consultations with healthcare professionals who can assess their situation, provide guidance, and prescribe emergency contraception if deemed appropriate. This process may include video calls, chat services, or secure messaging. Telemedicine and e-commerce have the potential to expand access to emergency contraception to underserved areas or regions with limited access to healthcare facilities or pharmacies.

Key Market Players

• Afaxys Pharma LLC
• Bayer AG
• Combe Inc.
• Foundation Consumer Healthcare LLC
• Gedeon Richter Plc
• HLL Lifecare Ltd.
• Knoll Healthcare Pvt. Ltd.
• Laboratoire HRA Pharma SAS
• Lupin Ltd.
• Mankind Pharma Ltd.

Report Scope:

In this report, the Global Emergency Contraceptive Pills Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Emergency Contraceptive Pills Market, By Type:

• Combination Pills
• Progesterone Pills
• Others

Emergency Contraceptive Pills Market, By Distribution Channel:

• Retail Stores
• Online Stores
• Others

Emergency Contraceptive Pills Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Emergency Contraceptive Pills Market.

Available Customizations:

Global Emergency Contraceptive Pills Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Emergency Contraceptive Pills Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Combination Pills, Progesterone Pills, Others)
  • 5.2.2. By Distribution Channel (Retail Stores, Online Stores, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Emergency Contraceptive Pills Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Emergency Contraceptive Pills Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. India Emergency Contraceptive Pills Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Australia Emergency Contraceptive Pills Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Distribution Channel
  • 6.3.4. Japan Emergency Contraceptive Pills Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Distribution Channel
  • 6.3.5. South Korea Emergency Contraceptive Pills Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Distribution Channel

7. Europe Emergency Contraceptive Pills Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Emergency Contraceptive Pills Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Emergency Contraceptive Pills Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. Spain Emergency Contraceptive Pills Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Emergency Contraceptive Pills Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. United Kingdom Emergency Contraceptive Pills Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Distribution Channel

8. North America Emergency Contraceptive Pills Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Emergency Contraceptive Pills Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. Mexico Emergency Contraceptive Pills Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Canada Emergency Contraceptive Pills Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Distribution Channel

9. South America Emergency Contraceptive Pills Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Emergency Contraceptive Pills Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Emergency Contraceptive Pills Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Emergency Contraceptive Pills Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Emergency Contraceptive Pills Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Emergency Contraceptive Pills Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Emergency Contraceptive Pills Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Emergency Contraceptive Pills Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Emergency Contraceptive Pills Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Afaxys Pharma LLC
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Bayer AG
• 16.3. Combe Inc.
• 16.4. Foundation Consumer Healthcare LLC
• 16.5. Gedeon Richter Plc
• 16.6. HLL Lifecare Ltd.
• 16.7. Knoll Healthcare Pvt. Ltd.
• 16.8. Laboratoire HRA Pharma SAS
• 16.9. Lupin Ltd.
• 16.10.Mankind Pharma Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer